Point-of-care testing: the over-the-counter pregnancy and fertility testing market

 
• By InteLab Corporation

The market for over-the-counter (OTC) home pregnancy and fertility testing products is mature, and is growing at a slower rate than the overall in vitro diagnostic (IVD) market worldwide. Sales were estimated at $584m worldwide in 2009, and are forecast to grow at 6.5% over the 2010-2015 interval. The market has been consolidating over the past few years, with the majority (almost 75%) attributable to three manufacturers. Pregnancy and fertility test kits are now sold in most retail drugstores and pharmacies in the developed world.

The market for over-the-counter (OTC) home pregnancy and fertility testing products is mature, and is growing at a slower rate than the overall in vitro diagnostic (IVD) market worldwide. Sales were estimated at $584m worldwide in 2009, and are forecast to grow at 6.5% over the 2010-2015 interval. The market has been consolidating over the past few years, with the majority (almost 75%) attributable to three manufacturers. Pregnancy and fertility test kits are now sold in most retail drugstores and pharmacies in the developed world.

The history of urine-based pregnancy testing dates to ancient Egyptian times. Papyrus documents from that era describe a test in...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight